Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:58
07/13/20
07/13
18:58
07/13/20
18:58
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, VNDA

Vanda Pharmaceuticals

$11.37 /

-0.125 (-1.09%)

, FREQ

Frequency Therapeutics

$20.43 /

-2.4 (-10.51%)

, EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, BA

Boeing

$175.62 /

-2.825 (-1.58%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, ALT

Altimmune

$24.88 /

+2.56 (+11.47%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
06/09/20 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
03/16/20
Fly Intel: Top five analyst downgrades
03/16/20 Oppenheimer
Vanda Pharmaceuticals downgraded to Underperform at Oppenheimer on Hetlioz risks
FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
BA Boeing
$175.62 /

-2.825 (-1.58%)

07/09/20
Emirates tells Bloomberg Boeing 777X likely to miss 2021 debut
07/08/20 Bernstein
Bernstein downgrades Spirit AeroSystems on slower delivery recovery
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
ALT Altimmune
$24.88 /

+2.56 (+11.47%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

  • 14
    Jul
  • 14
    Jul
  • 09
    Jan
  • 03
    Oct
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

Initiation
Frequency Therapeutics initiated with an Outperform at Oppenheimer » 16:10
07/13/20
07/13
16:10
07/13/20
16:10
FREQ

Frequency Therapeutics

$20.60 /

-2.23 (-9.77%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson initiated coverage of Frequency Therapeutics with an Outperform rating and $36 price target. The analyst said that, given the substantial market opportunity and limited treatment options available, he believes Frequency's FX-322 holds the promise to "revolutionize" the treatment of hearing loss.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

  • 03
    Oct
FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

Over a month ago
Conference/Events
Healthcare Financial Management Association to hold a virtual conference » 08:56
06/24/20
06/24
08:56
06/24/20
08:56
MTBC

MTBC

$8.50 /

-0.26 (-2.97%)

, NVZMY

Novozymes

$0.00 /

+ (+0.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVAX

Novavax

$69.66 /

+3.72 (+5.64%)

, MRK

Merck

$77.11 /

+0.4 (+0.52%)

, LOGI

Logitech

$62.73 /

-0.32 (-0.51%)

, REGN

Regeneron

$628.72 /

+0.81 (+0.13%)

, RDY

Dr. Reddy's

$54.33 /

+1.04 (+1.95%)

, FREQ

Frequency Therapeutics

$22.68 /

-0.47 (-2.03%)

, RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

, TRVI

Trevi Therapeutics

$5.71 /

+0.26 (+4.77%)

, CSU

Capital Senior Living

$0.76 /

-0.037 (-4.64%)

, NVO

Novo Nordisk

$67.93 /

-0.005 (-0.01%)

HFMA 2020 Digital Annual…

HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

06/22/20 H.C. Wainwright
MTBC upgraded to Buy from Neutral at H.C. Wainwright
06/02/20 Ladenburg
MTBC initiated with a Buy at Ladenburg
03/03/20
LD Micro to hold a virtual conference
03/02/20
Fly Intel: Top five analyst downgrades
NVZMY Novozymes
$0.00 /

+ (+0.00%)

05/12/20 Credit Suisse
Novozymes downgraded to Underperform from Outperform at Credit Suisse
04/01/20 Goldman Sachs
Novozymes downgraded to Sell from Buy at Goldman Sachs
03/13/20
Goldman Sachs to hold a conference
01/14/20 Exane BNP Paribas
Novozymes downgraded to Neutral from Outperform at Exane BNP Paribas
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
NVAX Novavax
$69.66 /

+3.72 (+5.64%)

06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
MRK Merck
$77.11 /

+0.4 (+0.52%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
LOGI Logitech
$62.73 /

-0.32 (-0.51%)

06/24/20 Wedbush
Logitech downgraded to Neutral at Wedbush with limited multiple expansion ahead
06/24/20 Wedbush
Logitech downgraded to Neutral from Outperform at Wedbush
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
05/21/20
Fly Intel: Top five analyst downgrades
REGN Regeneron
$628.72 /

+0.81 (+0.13%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

09/03/19 Barclays
Capital Senior Living initiated with an Underweight at Barclays
NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

Options
Thirteen new option listings and four option delistings on May 28th » 08:30
05/28/20
05/28
08:30
05/28/20
08:30
CFRX

ContraFect

$5.35 /

-0.045 (-0.83%)

, FREQ

Frequency Therapeutics

$18.27 /

+0.8 (+4.58%)

, HARP

Harpoon Therapeutics

$21.77 /

-3.23 (-12.92%)

, HOOK

Hookipa Pharma

$11.23 /

+0.73 (+6.95%)

, HSTO

Histogen

$4.61 /

+4.054 (+729.14%)

, IFRX

InflaRx

$8.36 /

+0.2 (+2.45%)

, KNSA

Kiniksa

$20.86 /

-0.89 (-4.09%)

, KZR

Kezar Life Sciences

$5.30 /

+0.05 (+0.95%)

, LQDA

Liquidia Technologies

$9.03 /

+0.05 (+0.56%)

, OVID

Ovid Therapeutics

$5.71 /

-0.97 (-14.52%)

, PRVL

Prevail Therapeutics

$16.83 /

-0.38 (-2.21%)

, CNAT

Conatus

$0.00 /

+ (+0.00%)

, CORV

Correvio

$0.42 /

+ (+0.00%)

, CTRC

Centric Brands

$0.19 /

-0.0279 (-12.65%)

, UNT

Unit Corp.

/

+

New option listings for…

New option listings for May 28th include ContraFect (CFRX), Centric Brands Inc (CTRCQ), Frequency Therapeutics Inc (FREQ), Harpoon Therapeutics Inc (HARP), HOOKIPA Pharma Inc (HOOK), Histogen Inc (HSTO), InflaRx NV (IFRX), Kiniksa Pharmaceuticals Ltd (Class A Stock) (KNSA), Kezar Life Sciences Inc (KZR), Liquidia Technologies Inc (LQDA), Ovid Therapeutics (OVID), Prevail Therapeutics Inc (PRVL), and Unit Corp (UNTCQ). Option delistings effective May 28th include Conatus Pharmaceuticals Inc (CNAT), Correvio Pharma Corporation (CORV), Centric Brands Inc (CTRC), and Unit Corp (UNT).

ShowHide Related Items >><<
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HSTO Histogen
$4.61 /

+4.054 (+729.14%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CORV Correvio
$0.42 /

+ (+0.00%)

CNAT Conatus
$0.00 /

+ (+0.00%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
06/11/19 Maxim
ContraFect initiated with a Buy at Maxim
FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Harpoon Therapeutics
02/28/20
Fly Intel: Top five analyst initiations
02/27/20 Truist
Harpoon Therapeutics initiated with a Buy at SunTrust
HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
HSTO Histogen
$4.61 /

+4.054 (+729.14%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

05/21/20 BMO Capital
InflaRx price target raised to $7 from $4 at BMO Capital
05/21/20 Raymond James
Raymond James doubles InflaRx price target to $20 ahead of COVID data
05/21/20 Raymond James
InflaRx price target raised to $20 from $10 at Raymond James
04/30/20 Raymond James
InflaRx upgraded to Outperform from Market Perform at Raymond James
KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

05/14/20 Piper Sandler
Prevail's 'quiet' Q1 report 'a victory in this environment,' says Piper Sandler
04/27/20 Piper Sandler
Prevail 20% pullback brings 'unique' buying opportunity, says Piper Sandler
04/09/20
Fly Intel: Top five analyst initiations
04/09/20 Piper Sandler
Prevail Therapeutics initiated with an Overweight at Piper Sandler
CNAT Conatus
$0.00 /

+ (+0.00%)

CORV Correvio
$0.42 /

+ (+0.00%)

12/11/19 H.C. Wainwright
Correvio downgraded to Neutral from Buy at H.C. Wainwright
09/03/19 Cantor Fitzgerald
Correvio initiated with an Overweight at Cantor Fitzgerald
CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

UNT Unit Corp.
/

+

03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Unit Corp. downgraded to Underweight from Equal Weight at Stephens
01/06/20 Raymond James
Unit Corp. downgraded at Raymond James on commodity price weakness
01/06/20 Raymond James
Unit Corp. downgraded to Underperform from Market Perform at Raymond James
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

Downgrade
JPMorgan downgrades Frequency Therapeutics on unclear data timelines » 09:04
05/18/20
05/18
09:04
05/18/20
09:04
FREQ

Frequency Therapeutics

$19.39 /

+2.345 (+13.76%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama downgraded Frequency Therapeutics to Neutral from Overweight with a price target of $27, down from $28. The analyst continues to believe that the company's lead asset FX-322 for sensorineural hearing loss has shown encouraging Phase 1/2 single dose data. However, 2020 appears to be turning out to be more of a clinical execution year for the company, Rama tells investors in a research note. Further, the primary clinical catalyst for the Frequency is Phase 2a single/repeat dose study results for which timelines are currently not well defined, adds the analyst. Rama believes enrollment completion and timelines to data "are in flux" in the midst of the COVID-19 pandemic, putting risk on the company's prior guidance of second half of 2020. Rama believes Frequency shares will perform in line with broader markets until timelines to data are better defined.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$19.39 /

+2.345 (+13.76%)

FREQ Frequency Therapeutics
$19.39 /

+2.345 (+13.76%)

05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Frequency Therapeutics initiated with a Buy at Goldman Sachs
FREQ Frequency Therapeutics
$19.39 /

+2.345 (+13.76%)

Downgrade
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan » 05:33
05/18/20
05/18
05:33
05/18/20
05:33
FREQ

Frequency Therapeutics

$19.39 /

+2.345 (+13.76%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama downgraded Frequency Therapeutics to Neutral from Overweight with a $27 price target.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$19.39 /

+2.345 (+13.76%)

FREQ Frequency Therapeutics
$19.39 /

+2.345 (+13.76%)

10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Frequency Therapeutics initiated with a Buy at Goldman Sachs
FREQ Frequency Therapeutics
$19.39 /

+2.345 (+13.76%)

Hot Stocks
Frequency Therapeutics provides update on COVID-19 impact to business » 07:44
05/14/20
05/14
07:44
05/14/20
07:44
FREQ

Frequency Therapeutics

$17.20 /

+0.53 (+3.18%)

Frequency's offices…

Frequency's offices are located in states that are currently under mandated lock down orders and/or stay at home advisories, though in Massachusetts, biotechnology firms have been deemed essential and are exempted from such orders. At present, the majority of Frequency employees are working from home, while certain necessary laboratory employees have periodically worked in the lab to ensure that essential experiments continue. The Farmington, Connecticut research site, co-located with the University of Connecticut, has paused activity and this site is expected to re-open when non-essential State offices are permitted to do so. Key experiments have been transitioned to the company's offices in Woburn, Massachusetts and third parties and contract research organizations have been engaged to advance certain projects.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$17.20 /

+0.53 (+3.18%)

FREQ Frequency Therapeutics
$17.20 /

+0.53 (+3.18%)

10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Frequency Therapeutics initiated with a Buy at Goldman Sachs
FREQ Frequency Therapeutics
$17.20 /

+0.53 (+3.18%)

Earnings
Frequency Therapeutics reports Q1 EPS (16c), consensus (17c) » 07:43
05/14/20
05/14
07:43
05/14/20
07:43
FREQ

Frequency Therapeutics

$17.20 /

+0.53 (+3.18%)

Reports Q1 revenue…

Reports Q1 revenue $7.26M, consensus $5.86M. "Our Phase 2a study of FX-322 for sensorineural hearing loss continues to enroll subjects at a number of clinical sites, despite challenges from the COVID-19 pandemic. Overall, we are pleased with our progress and we deeply appreciate the work of our investigators, site staff and the engagement of the patients participating in the study during this challenging period," said Frequency Therapeutics CEO David Lucchino.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$17.20 /

+0.53 (+3.18%)

FREQ Frequency Therapeutics
$17.20 /

+0.53 (+3.18%)

10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Frequency Therapeutics initiated with a Buy at Goldman Sachs
Hot Stocks
Frequency Therapeutics announces data from FX-322 exploratory clinical study » 07:19
05/14/20
05/14
07:19
05/14/20
07:19
FREQ

Frequency Therapeutics

$17.20 /

+0.53 (+3.18%)

Frequency Therapeutics…

Frequency Therapeutics announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every patient and that anatomical factors did not prevent the active agents of FX-322 from reaching the cochlea. Further, the levels of FX-322 in the cochlea were predicted to reach the therapeutically active range of the treatment. FX-322 is Frequency's lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss, or SNHL. A Phase 1/2 study of FX-322 previously demonstrated statistically significant and clinically meaningful improvements in key measures of hearing function in patients with SNHL. The exploratory study, initiated late in 2019, was conducted at the Hannover Medical Centre in Hannover, Germany. Results were based on an analysis of cochlear fluid, known as perilymph, obtained intraoperatively from patients undergoing cochlear implant surgery. Each patient received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. In the study, seven subjects received a single dose of FX-322 at the same dose level given in the company's Phase 1/2 study and its ongoing Phase 2a study. Levels of both molecules that make up FX-322 were measured in all patients. The presence of round window membrane mucosal folds in certain subjects did not prevent the entry of FX-322 into the cochlea. Both agents that make up FX-322 were also predicted to achieve therapeutically active drug levels in the high frequency range of the cochlea, based on computer models. Study subjects were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$17.20 /

+0.53 (+3.18%)

FREQ Frequency Therapeutics
$17.20 /

+0.53 (+3.18%)

10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Frequency Therapeutics initiated with a Buy at Goldman Sachs
Over a quarter ago
Conference/Events
Frequency Therapeutics management to meet with JPMorgan » 04:55
02/13/20
02/13
04:55
02/13/20
04:55
FREQ

Frequency Therapeutics

$25.30 /

-0.08 (-0.32%)

Meeting to be held in…

Meeting to be held in Chicago on February 13 hosted by JPMorgan.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$25.30 /

-0.08 (-0.32%)

10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Frequency Therapeutics initiated with a Buy at Goldman Sachs

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.